Vol. 6 No. 7 (2026): July
Reimbursement Reviews

Caplacizumab (Cablivi)

decorative image of the issue cover

Published July 31, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Caplacizumab (Cablivi), 11 mg, powder for solution, IV or SC injection
  • Indication: For the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.